I believe this pps rise is due to Dr. Urano's article scheduled to be released today. I suspect he will report that he'll be using a combination of : Stem cells, "small molecules," and Recombinant MANF (our patent) at various stages of his wolframs and eye damage treatment.
It will be interesting to see if his small molecule method is still preferred by him for treating wolframs, but I got to believe recombinant MANF injections are still a part of the eye therapy.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links